InterCure Ltd. (NASDAQ:INCR) Short Interest Down 14.6% in March

InterCure Ltd. (NASDAQ:INCR) was the target of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 90,200 shares, a decrease of 14.6% from the March 15th total of 105,600 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 90,900 shares, the days-to-cover ratio is currently 1.0 days.

InterCure Stock Down 2.9 %

NASDAQ:INCR opened at $2.36 on Friday. InterCure has a fifty-two week low of $0.99 and a fifty-two week high of $2.92. The stock has a market cap of $107.55 million, a PE ratio of 18.15 and a beta of 1.73. The firm’s fifty day simple moving average is $2.07 and its 200-day simple moving average is $1.54.

Hedge Funds Weigh In On InterCure

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG boosted its position in shares of InterCure by 222.3% in the 3rd quarter. UBS Group AG now owns 6,337 shares of the company’s stock worth $29,000 after buying an additional 4,371 shares in the last quarter. Citigroup Inc. boosted its position in shares of InterCure by 9,567.9% in the 1st quarter. Citigroup Inc. now owns 5,124 shares of the company’s stock worth $36,000 after buying an additional 5,071 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of InterCure by 756.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,309 shares of the company’s stock worth $37,000 after buying an additional 5,572 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of InterCure in the 3rd quarter worth about $58,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of InterCure in the 1st quarter worth about $91,000. 8.34% of the stock is owned by institutional investors and hedge funds.

InterCure Company Profile

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.